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Abstract A clinical trial was initiated to evaluate the
recommended dose of cyclophosphamide in combination
with bortezomib and dexamethasone as induction treatment
before stem cell transplantation for younger patients with
newly diagnosed multiple myeloma (MM). Thirty patients
were treated with three 21-day cycles of bortezomib
1.3 mg/m
2 on days 1, 4, 8, and 11 plus dexamethasone
40 mg on the day of bortezomib injection and the day after
plus cyclophosphamide at 900, 1,200, or 1,500 mg/m
2 on
day 1. The maximum tolerated dose of cyclophosphamide
was defined as 900 mg/m
2. At this dose level, 92% of
patients achieved at least a partial response. The overall
response rate [complete response (CR) plus partial response
(PR)] across all dose levels was 77%, with a 10% CR rate.
No patient experienced progressive disease. The most
frequent adverse events were hematological and gastroin-
testinal toxicities as well as neuropathy. The results suggest
that bortezomib in combination with cyclophosphamide at
900 mg/m
2 and dexamethasone is an effective induction
treatment for patients with newly diagnosed MM that
warrants further investigation.
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Introduction
For patients younger than 65 years with newly diagnosed
multiple myeloma (MM), high-dose melphalan followed by
stem cell transplantation (SCT) is considered the standard
of care. Induction treatment before SCT typically consists
of vincristine, doxorubicin, and dexamethasone. With this
regimen, response rates are in the range of 50–60% with a
generally low incidence of complete responses (CRs;
<10%) [1]. It has been suggested that the inclusion of
novel agents, such as thalidomide, lenalidomide, and
bortezomib, in induction treatments improves response
rates over those achieved with traditional regimen and
may improve overall outcomes for patients [2].
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Neuss, GermanyBortezomib (Velcade®; Millennium Pharmaceuticals, Cam-
bridge, MA, USA and Johnson & Johnson Pharmaceutical
Research and Development LLC, La Jolla, CA, USA) is a
selective and reversible inhibitor of the proteasome that has
demonstrated efficacy in the relapsed and relapsed/refractory
setting. In patients with a relapse after one to three prior
therapies, an overall response rate of 43% was noted, with a
16% complete response (CR)+near CR rate [3]. Moreover, the
overall survival with single-agent bortezomib for relapsed
myeloma was 29.8 months. The combination of bortezomib
with conventional cytotoxic therapy suggested synergistic
anti-myeloma activity in preclinical studies [4, 5]. Further-
more, a number of trials have shown increased overall and
complete response rates when bortezomib is combined with
conventional chemotherapy and steroids [6–9].
Bortezomib is currently undergoing investigation in
frontline treatment in both the transplant and non-
transplant setting. A number of phase 2 studies and, more
recently, two phase 3 studies are demonstrating that
inclusion of bortezomib in induction regimen increases
response rates pre- as well as post-transplant [2, 10–12].
We have previously shown that bortezomib in combination
with cyclophosphamide and dexamethasone results in a high
overall response rate with manageable adverse events in
patients with relapsed/refractory MM, prompting the investiga-
tion of this three-drug combination in the frontline setting [6].
These results in relapsed myeloma have recently been
c o n f i r m e db yo t h e r s[ 13, 14]. The current trial was initiated to
examine the combination of fixed doses of bortezomib and
dexamethasone with varying doses of cyclophosphamide, with
the objective of defining a recommended dose of cyclophos-
phamide, which then will be further investigated. The results
of this dose-finding study are reported in this paper.
Materials and methods
Patients
From March 2006 to February 2007, 31 patients were
enrolled at five study centers in Germany. Major inclusion
criteria were newly diagnosed MM requiring therapy, age
18–60 years, leukocytes ≥3.0×10
3/mm
3, absolute neutro-
phil count ≥1.5×10
3/mm
3, platelets ≥75×10
3/mm
3, creati-
nine clearance >30 ml/min, aspartate aminotransferase and
alanine aminotransferase <2.5×upper limit of normal
(ULN), bilirubin <1.5×ULN. Prior localized radiotherapy
and short-course dexamethasone were allowed.
The following were major exclusion criteria: non-secretory
myeloma; prior systemic treatment for symptomatic myelo-
ma; hypersensitivity to bortezomib, boron, mannitol, or
cyclophosphamide; pre-existing peripheral neuropathy of
grade 2 or greater intensity; cancer other than MM within
5 years before enrollment, with the exception of basal cell
carcinoma or cervical cancer in situ; active hepatitis; and HIV
infection. Females of childbearing potential were required to
have a negative pre-treatment urine pregnancy test and
contraception throughout treatment.
The study was conducted in accordance with the
Declaration of Helsinki including all current amendments.
It has been registered at the European Clinical Trials
Database (EudraCT no. 2005-003907-27). The study
protocol was approved by the local ethics committee at
each participating site. All patients provided written
informed consent. Data were controlled by an independent
clinical research organization.
Study design and treatment schedule
Thisopen-label, prospective trial was designedtoevaluatethe
maximum tolerated dose of cyclophosphamide in combina-
tionwithbortezomibanddexamethasone.Thirtypatientswith
newly diagnosed MM were scheduled to receive a maximum
of three 21-day cycles of bortezomib 1.3 mg/m
2 as a single
bolus i.v. twice weekly (on days 1, 4, 8, and 11) plus
dexamethasone 40 mg p.o. on the day of and the day after
bortezomib plus cyclophosphamide i.v. on day 1 (Fig. 1).
The following cyclophosphamide dose levels were scheduled
to be examined: 600, 900, 1,200, and 1,500 mg/m
2.T h e
initial dose of cyclophosphamide was 1,200 mg/m
2.I fn o
dose-limiting toxicity (DLT) occurred, cyclophosphamide
was to be increased to 1,500 mg/m
2. An extension to six
patients was to be done if DLT was documented in one out
of three patients at 1,200 mg/m
2. If more than two sixths of
the patients experienced a DLT, cyclophosphamide was to be
reduced to 900 mg/m
2 and then to 600 mg/m
2.
If two out of three patients experienced a DLT, an
immediate dose reduction was mandatory.
DLT was defined as either hematological toxicity grade
4, non-hematological toxicity ≥ grade 3 (except nausea,
vomiting, and alopecia) or neuropathy grade 2 with pain
occurring during the first treatment cycle.
The maximum tolerated dose for cyclophosphamide was
defined as the dose level at which the incidence of DLTs
was less than 33%.
Recommended concomitant medication consisted of pro-
phylactic antiviral medication, prophylaxis against pneumo-
cystis carinii, oral non-absorbable antifungal medication, and
bisphosphonates. In addition, anti-emetics, cytokines, uromi-
texan, and intravenous immunoglobulins were allowed.
Assessment of efficacy and safety
Response was evaluated following the European Group for
Blood and Marrow Transplantation criteria [15]. Briefly, a
partial response (PR) was defined as >50% reduction of
1126 Ann Hematol (2009) 88:1125–1130monoclonal immunoglobulin and >90% reduction of light
chain proteinuria; for a minor response (MR), the
corresponding cut points were 25% and 50%, respectively.
CR required a negative immunofixation in serum and urine.
PD without prior CR was determined by a ≥25% increase in
monoclonal gammopathy or light chain proteinuria or the
occurrence of new lytic bone lesions.
Baseline evaluations included physical examination,
blood counts, hepatic and renal function tests, bone marrow
aspirate for centrally performed (PL) molecular cytogenetic
analyses (fluorescence in situ hybridization) and biopsy,
serum and urine protein electrophoreses, and quantitation of
serum immunoglobulins and urinary light chains, β2M and
C reactive protein. A chest X-ray and a complete
radiological bone survey were also performed. Safety was
assessed throughout the study by physical examinations,
recording of vital signs, toxicity assessments, and labora-
tory tests (hematology, clinical chemistry). All patients that
received at least one dose of the study drugs were included
in the toxicity evaluation.
Study objectives and statistical analysis
The primary objective of this study was to establish the
optimal dose of cyclophosphamide in combination with
fixed doses of bortezomib and dexamethasone.
Secondary objectives were to evaluate the safety and
tolerability of an induction therapy with bortezomib,
dexamethasone, and cyclophosphamide.
Outcome was analyzed on an intention-to-treat basis.
Results
Patient characteristics
Of 31 patients enrolled, one patient had to be excluded
from the study for not meeting eligibility criteria. Baseline
characteristics of the 30 patients who entered the active
treatment phase are shown in Table 1. A number of patients
had received supportive treatment for myeloma before
study enrollment: 21 patients had received single pulses
of dexamethasone, and nine patients had undergone
localized radiotherapy.
In total, 13 (43.3%) patients were treated with an initial
dose of cyclophosphamide 900 mg/m
2, 13 (43.3%) patients
with 1,200 mg/m
2, and four (13.3%) patients with
1,500 mg/m
2. Twenty-two patients (73.3%) completed all
three scheduled treatment cycles. Twenty-seven patients are
evaluable for cyclophosphamide dose definition. Three
patients had to be excluded from evaluation for dose
definition because of major protocol deviations.
Day
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Bortezomib  
1.3 mg/m
2 IV 
X X  X X
Dexamethasone  
40 mg PO 
X X  X X X X X X
Cyclophosphamide  
IV 
X 
Fig. 1 Treatment schedule
Table 1 Patient characteristics at baseline (n=30)
Characteristic Values
Gender
Male (n)1 6
Mean age (years) 50.8
Range (years) 36–60
Durie–Salmon stage II/III, n 8/22
Myeloma type, n
IgG 20
IgA 7
Light chain only 3
Light chain, n
κ 19
λ 11
Cytogenetics, n
a
del(13) 12
del(17p13) 3
t(4;14) 5
Other 10
No changes 4
aCytogenetics available in twenty three patients
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Three patients were treated with cyclophosphamide at an
initial dose of 1,200 mg/m
2 without any DLT occurring in
the first treatment cycle. Therefore, the dose of cyclophos-
phamide was increased to 1,500 mg/m
2. At this dose level,
two DLTs (both leukopenia) occurred in two of three
treated patients. As a result, the cyclophosphamide dose
was reduced to 1,200 mg/m
2, and six further patients were
treated at this dose level (in addition to the three patients
who were initially treated at 1,200 mg/m
2). In two of the six
patients, a DLT was observed (one leukopenia and one
neutropenia). To test this dose level further, four additional
patients were treated with cyclophosphamide 1,200 mg/m
2.
In two of these patients, a DLT occurred (leukopenia in
both cases), and as a result, the dose of cyclophosphamide
was reduced to 900 mg/m
2. A total of 13 patients were
treated at 900 mg/m
2 with one DLT (pneumonia) occurring.
The dose of 900 mg/m
2 was therefore defined as the
maximum tolerated dose for cyclophosphamide in combi-
nation with bortezomib and dexamethasone.
Efficacy
All 30 patients in the intent-to-treat population were
evaluable for response. Overall, the response rate (CR+
Cyclophosphamide Dose level (mg/m
2) n CR PR MR SD PD CR+PR (%)
900 13 1 11 1 –– 92
1,200 13 2 7 2 2 – 69
1,500 4 – 2 – 2 – 50
Total 30 3 20 3 4 – 77
Table 2 Response to treatment
(n=30)
Table 3 Adverse events of major clinical concern(all grades) irrespective of relation to study drug treatment (n=30 patients who received at least
on dose of study drugs)
Adverse event (maximum grade per patient) Grade 1 Grade 2 Grade 3 Grade 4
Number Percent Number Percent Number Percent Number Percent
Anemia 5 17 6 20 0 0
Leukocytopenia 5 17 4 13 7 23 7 23
Infection 7 23 13 43 1 3 1 3
Herpes zoster 0 1 3 0 0
Thrombocytopenia 12 40 5 17 2 7 0
Bleeding 1 3 0 1 3 0
Neuropathy 12 40 4 13 3 10 0
Fatigue 3 10 4 13 0 0
Constipation 6 20 1 3 0 0
Diarrhea 2 7 3 10 0 0
Liver, AST/ASL 3 10 2 7 0 0
Renal failure 0 0 1 3 0
Hyperglycemia 1 3 0 0 0
Cardiovascular events 3 10 0 0 0
Hypotension 1 3 0 0 0
Dyspnea 5 17 0 1 3 0
Edema 4 13 0 0 0
Venous thromboembolic events 0 2 7 0 0
Myopathy 0 0 0 0
Mucositis 1313 0 0
Skin 8 27 1 3 0 0
The adverse event category “infection” summarizes the following events: infection, pneumonia, pharyngitis, upper respiratory tract infection,
bronchitis, febrile aplasia, febrile neutropenia, respiratory tract infection bacterial, tonsillitis, urinary tract infection, rhinitis, and nasopharyngitis.
AST serum aspartate amino transferase, ASL serum alanine aminotransferase
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PR (67%), and three (10%) MR (Table 2). No patient
experienced progressive disease.
In the subgroup of patients who received the maximum
tolerated dose, the overall response rate was 92% with one
CR, 11 PRs, and one MR, with a median time to best
response of 46 days.
Patients with high-risk cytogenetics (t[4;14], or 17p
deletion, n=8) showed a slightly inferior overall re-
sponse rate compared to patients without these changes
(n=15; 62.5% versus 86.5% ≥PR); when patients with
13q deletion were included in the high-risk group, the
overall response rate was inferior compared to patients
with standard-risk cytogenetics (61.5% versus 100%
≥PR).
To date, stem cell harvest has been carried out within the
subsequent trial, the DSMM XI study in 28 patients. All
patients mobilized well with a median of one collection
procedure. Following subsequent high-dose melphalan
therapy, median time to neutrophil engraftment was 13 days
(range, 1–20); median time to platelet engraftment was
15 days (range, 8–30).
Safety
All patients experienced at least one adverse event. The
most frequent adverse events were myelosuppression,
gastrointestinal disorders, fatigue, and neuropathy (Table 3).
In addition, one patient who had not received antiviral
prophylaxis experienced grade 2 herpes zoster. Most
adverse events were National Cancer Institute Common
Toxicity Criteria grades 1–2.
Adverse events leading to premature discontinuation of
bortezomib or cyclophosphamide were documented in five
(16.7%) patients.
Serious adverse events occurred in eight of 30 (26.7%)
patients. In the 900 mg/m
2 group, serious adverse events
were dose-limiting pneumonia, cholelithiasis, and neural-
gia. In the 1,200 mg/m
2 group, the following serious
adverse events were noted: two cases of dose-limiting
leukopenia, one case of pneumonia, and one case of
intervertebral disc protrusion. In the 1,500 mg/m
2 group,
serious adverse events included thrombocytopenia, urethral
hemorrhage, acute renal failure, dose-limiting infection
(which was subsequently corrected as being just a serious
adverse event but not DLT since the patient was classified
as drop out and therefore not evaluable for DLT) and two
cases of leukopenia.
Two cases of dose-limiting leukopenia were not consid-
ered to be serious adverse events.
No deaths were reported during the conduct of the
study.
Discussion
We initiated a trial to evaluate the optimal dose of
cyclophosphamide in combination with fixed dose borte-
zomib and dexamethasone as induction treatment before
SCT and to evaluate efficacy and safety. This combination
obviates the risks associated with the repeated placing and
maintenance of indwelling central venous catheters for
phlebotoxic drugs, such as vincristine or doxorubicin,
which are widely used for pre-transplant induction in
myeloma. Instead this treatment can be administered on
an outpatient basis. The study defined that cyclophospha-
mide at 900 mg/m
2 in combination with standard doses of
bortezomib and dexamethasone is the recommended dose
that should be investigated further. At the maximum
tolerated dose of cyclophosphamide, a high overall
response rate was achieved with a short time to response.
The lower response rates observed at the higher cyclophos-
phamide doses may be due to the fact that in patients with a
DLT response was assessed early after the first cycle
corresponding to the end of study treatment. Patients in
the 900 mg/m
2 group, on the other hand, typically received
all three cycles of therapy before response was assessed.
T h eh i g hr e s p o n s er a t ea c h i e v e da tt h em a x i m u m
tolerated dose is in line with the results of other bortezomib
combination studies in the frontline setting [2, 10–12, 16].
The recently presented Canadian phase 2 trial investigating
the combination of bortezomib, cyclophosphamide, and
dexamethasone as induction treatment differed from that in
our study in that cyclophosphamide was given at 300
mg/m
2 weekly (on days 1, 8, 15, and 22) and dexameth-
asone 40 mg was administered on days 1–4, 9–12, and 17–
20 [16]. Nevertheless, the results of the Canadian study
agree with those of our own study, suggesting that the
combination of bortezomib, cyclophosphamide, and dexa-
methasone is effective, inducing rapid and deep responses.
Consistent with previous data, our results demonstrate
that bortezomib-based regimen lead to responses even in
patients with cytogenetic abnormalities [17–19]. The
response rate appears to be reduced compared with that in
patients with standard-risk cytogenetics; however, the small
number of patients precludes a meaningful comparison.
Adverse events in our study were in line with those
observed in previous studies involving bortezomib, cyclo-
phosphamide, and dexamethasone [6]. Notably, no deep vein
thrombosis was seen, and only a single patient, who did not
receive antiviral prophylaxis, experienced herpes zoster.
Induction therapy with bortezomib/dexamethasone/cy-
clophosphamide neither adversely affected subsequent stem
cell mobilization nor engraftment after high-dose melpha-
lan, which is in accordance with previous reports of
bortezomib-based induction regimen [20].
Ann Hematol (2009) 88:1125–1130 1129Our results demonstrate that bortezomib in combination
with cyclophosphamide and dexamethasone is an effective
outpatient induction treatment for newly diagnosed MM.
The recommended dose of cyclophosphamide in this
combination is 900 mg/m
2. This schedule is currently being
evaluated as pre-transplant induction therapy in a prospec-
tive trial of the Deutsche Studiengruppe Multiples Myelom.
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